A Critical Role for Choline Kinase-alpha in the Aggressiveness of Bladder Carcinomas

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2009 May 19

PMID 19448670

Citations 34

Authors

E Hernando

J Sarmentero-Estrada

T Koppie

C Belda-Iniesta

V Ramirez de Molina

P Cejas

C Ozu

C Le

J J Sanchez

M Gonzalez-Baron

J Koutcher

C Cordon-Cardo

B H Bochner

J C Lacal

A Ramirez de Molina

Affiliations

Soon will be listed here.

Abstract

Bladder cancer is one of the most common causes of death in industrialized countries. New tumor markers and therapeutic approaches are still needed to improve the management of bladder cancer patients. Choline kinase-alpha (ChoKalpha) is a metabolic enzyme that has a role in cell proliferation and transformation. Inhibitors of ChoKalpha show antitumoral activity and are expected to be introduced soon in clinical trials. This study aims to assess whether ChoKalpha plays a role in the aggressiveness of bladder tumors and constitutes a new approach for bladder cancer treatment. We show here that ChoKalpha is constitutively altered in human bladder tumor cells. Furthermore, in vivo murine models, including an orthotopic model to mimic as much as possible the physiological conditions, revealed that increased levels of ChoKalpha potentiate both tumor formation (P< or =0.0001) and aggressiveness of the disease on different end points (P=0.011). Accordingly, increased levels of ChoKalpha significantly reduce survival of mice with bladder cancer (P=0.05). Finally, treatment with a ChoKalpha-specific inhibitor resulted in a significant inhibition of tumor growth (P=0.02) and in a relevant increase in survival (P=0.03).

Citing Articles

Oxidative Stress and Reprogramming of Lipid Metabolism in Cancers.

Li S, Yuan H, Li L, Li Q, Lin P, Li K Antioxidants (Basel). 2025; 14(2).

PMID: 40002387 PMC: 11851681. DOI: 10.3390/antiox14020201.

Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics.

Jin H, Wang J, Wang Z, Xi M, Xia B, Deng K J Hematol Oncol. 2023; 16(1):103.

PMID: 37700339 PMC: 10498649. DOI: 10.1186/s13045-023-01498-2.

MALAT1 as a Regulator of the Androgen-Dependent Choline Kinase A Gene in the Metabolic Rewiring of Prostate Cancer.

De Martino S, Iorio E, Cencioni C, Aiello A, Spallotta F, Chirico M Cancers (Basel). 2022; 14(12).

PMID: 35740569 PMC: 9221206. DOI: 10.3390/cancers14122902.

Phosphatidylcholine-Derived Lipid Mediators: The Crosstalk Between Cancer Cells and Immune Cells.

de Freitas Saito R, Andrade L, Bustos S, Chammas R Front Immunol. 2022; 13:768606.

PMID: 35250970 PMC: 8889569. DOI: 10.3389/fimmu.2022.768606.

Role of magnetic resonance spectroscopy in differential diagnosis of solitary pulmonary lesions.

Hekimoglu A, Ergun O, Turan A, Turkmenoglu T, Hekimoglu B Diagn Interv Radiol. 2021; 27(6):710-715.

PMID: 34792024 PMC: 8621646. DOI: 10.5152/dir.2021.20419.

References

Glunde K, Bhujwalla Z . Choline kinase alpha in cancer prognosis and treatment. Lancet Oncol. 2007; 8(10):855-7. DOI: 10.1016/S1470-2045(07)70289-9. View

Quek M, Stein J, Nichols P, Cai J, Miranda G, Groshen S . Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol. 2005; 174(1):103-6. DOI: 10.1097/01.ju.0000163267.93769.d8. View

Ramirez de Molina A, Gallego-Ortega D, Sarmentero J, Banez-Coronel M, Martin-Cantalejo Y, Lacal J . Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis. Cancer Res. 2005; 65(13):5647-53. DOI: 10.1158/0008-5472.CAN-04-4416. View

Aoyama C, Liao H, Ishidate K . Structure and function of choline kinase isoforms in mammalian cells. Prog Lipid Res. 2004; 43(3):266-81. DOI: 10.1016/j.plipres.2003.12.001. View

Mullerad M, Bochner B, Adusumilli P, Bhargava A, Kikuchi E, Hui-Ni C . Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma. J Urol. 2005; 174(2):741-6. PMC: 1351159. DOI: 10.1097/01.ju.0000164730.38431.5c. View

Kikuchi E, Xu S, Ohori M, Matei C, Lupu M, Menendez S . Detection and quantitative analysis of early stage orthotopic murine bladder tumor using in vivo magnetic resonance imaging. J Urol. 2003; 170(4 Pt 1):1375-8. DOI: 10.1097/01.ju.0000075504.13456.41. View

Hernando E, Orlow I, Liberal V, Nohales G, Benezra R, Cordon-Cardo C . Molecular analyses of the mitotic checkpoint components hsMAD2, hBUB1 and hBUB3 in human cancer. Int J Cancer. 2001; 95(4):223-7. DOI: 10.1002/1097-0215(20010720)95:4<223::aid-ijc1038>3.0.co;2-l. View

Ramirez de Molina A, Sarmentero-Estrada J, Belda-Iniesta C, Taron M, Ramirez de Molina V, Cejas P . Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol. 2007; 8(10):889-97. DOI: 10.1016/S1470-2045(07)70279-6. View

Garraway L, Sellers W . Lineage dependency and lineage-survival oncogenes in human cancer. Nat Rev Cancer. 2006; 6(8):593-602. DOI: 10.1038/nrc1947. View

10.

Hernandez-Alcoceba R, Saniger L, Campos J, Nunez M, Khaless F, Gallo M . Choline kinase inhibitors as a novel approach for antiproliferative drug design. Oncogene. 1997; 15(19):2289-301. DOI: 10.1038/sj.onc.1201414. View

11.

Gallego-Ortega D, Ramirez de Molina A, Gutierrez R, Ramos M, Sarmentero J, Cejas P . Generation and characterization of monoclonal antibodies against choline kinase alpha and their potential use as diagnostic tools in cancer. Int J Oncol. 2006; 29(2):335-40. View

12.

Ramirez de Molina A, Banez-Coronel M, Gutierrez R, Rodriguez-Gonzalez A, Olmeda D, Megias D . Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res. 2004; 64(18):6732-9. DOI: 10.1158/0008-5472.CAN-04-0489. View

13.

Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, Martinez-Pineiro L, Sanchez J, Bonilla F . Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun. 2002; 296(3):580-3. DOI: 10.1016/s0006-291x(02)00920-8. View

14.

Rodriguez-Gonzalez A, Ramirez de Molina A, Banez-Coronel M, Megias D, Lacal J . Inhibition of choline kinase renders a highly selective cytotoxic effect in tumour cells through a mitochondrial independent mechanism. Int J Oncol. 2005; 26(4):999-1008. View

15.

Wu X . Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 2005; 5(9):713-25. DOI: 10.1038/nrc1697. View

16.

Glunde K, Raman V, Mori N, Bhujwalla Z . RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res. 2005; 65(23):11034-43. DOI: 10.1158/0008-5472.CAN-05-1807. View

17.

Weinstein I, Joe A . Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol. 2006; 3(8):448-57. DOI: 10.1038/ncponc0558. View

18.

Lu M, Wikman F, Orntoft T, Charytonowicz E, Rabbani F, Zhang Z . Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin Cancer Res. 2002; 8(1):171-9. View

19.

Al-Saffar N, Troy H, Ramirez de Molina A, Jackson L, Madhu B, Griffiths J . Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res. 2006; 66(1):427-34. DOI: 10.1158/0008-5472.CAN-05-1338. View

20.

Oliveira P, Colaco A, De la Cruz P L, Lopes C . Experimental bladder carcinogenesis-rodent models. Exp Oncol. 2006; 28(1):2-11. View